Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MCET BIG NEWS
MultiCell Technologies Files Milestone Patent to Treat Cancer
By BusinessWire
Last Update: 9/28/2006 4:01:27 PM Data provided by
SAN DIEGO, Sep 28, 2006 (BUSINESS WIRE) -- MultiCell Technologies, Inc. (MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced the filing of a milestone patent that provides a potential method for treating a range of malignant tumors using the Company's unique technologies to manipulate the immune system.
MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide. The new patent filing broadens protection of MultiCell's intellectual property portfolio, and further expands the Company's potential therapeutic development targets to include cancer.
The patent filing, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
"The implications for this patent-pending technology are far-reaching and could someday help treat the millions of patients suffering from various cancers," said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. "We believe that this patent further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics."
The Company's technology platforms include TLR and T-cell targeting to modulate both the innate and adaptive immune systems, thus enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting.
MultiCell's new patent provides a method for treatment of a tumor after clinical diagnosis. The method involves the loading of an antigen presenting cell with at least one tumor associated T-cell epitope attached to an IgG backbone to form an Ig-peptide molecule followed by administration of the Ig-peptide molecule in vivo in conjunction with MultiCell's dsRNA TLR therapeutic.
MultiCell has a therapeutic pipeline with drug candidates already in various advanced stages of human clinical trials. These therapies include:
-- MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.
-- MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models.
-- MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.
-- MCT-465 for the treatment of virus infection. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html.
SOURCE: MultiCell Technologies, Inc.
today should be interesting!!
just talked to ameritrade, fyi they said that they do not take any positions in any stock, and that we are at the mercy of the company as to when we recieve the divys, mine are showing up N/A we will find out tomorrow what up!!!!!
you havent recieved your shares yet, I have atrd and got my 22million a week ago
reminds me of IPRE
bad memories
anyone hear anything about that?
any hot picks tonight looking at tomorrow?
that is not really a pr, it is a sponsored/unsponsored mention of the company by a mailer. they send them out to highlight companies.
they did that to my cash before the stock settles. no info though
I AGREE!!!!!
fun week ahead
OT: watch DBDX, should be a wild week, hopefully BKMP will have some great news out this week too!!!!
"bid whacking" from my understanding is dumping your shares at the bid instead of selling into the run and selling at the ask. the problem with bidwacking is that it kills the run and brings the price down, while selling at the ask moves the price higher and keeps momentum upward. IMO
no one should sell this at the bid in the next week!
sell at the ask if you want to sell!
hey all, just read over the pr, where were they for the past 12 years, if they were not in their new location, and since they are glad to be "back in the diamond district"? any ideas, or anyone know? thanks, cant wait to hear some good news this week!
gotta love that:)
GOTTA LOVE THAT CLOSE .05$$$$$$$$$$$
HELL YA GBDX RUN BABY RUN COME MONDAY!!!
good luck, doubt youll get filled,
I would take .04 cause there is going to be some action monday!!!:)
me too!!!!:)
I would really like to see some strong buying into the close, but it is friday so probably not, monday should be fun!!! It would be great to see a big week next week!
i traded mine at .05 on accident thru ameritrade hope to get in soon if my wire goes through, stupid 3 day settling on buys
thats alot of shares? did yours go through?
let it be sooooooooo!!!!!!!:)
Hello everyone, I am in at the high side,
100,911 @ .0425
but i speculate on holding into next week
and seeing some GREEN$$$$$$$$
nice call,
hope so, lets make some $$$$ on DMSI while BKMP is low enough to load up on!!!!!!! BIG AM GAP
I assume you are in DMSI now, have you been watching this or just caught the pr?
analyze, what do you think this press release will do, do you think people will let it gap up in the morning?
i am holding 22 million at this time!
i sure hope it is!!!
nitey nite then
to be 3am honest.... wtf, dont post much but school and kiddies suckin my time, wish we could have hit higher than .0014 last run, but is all comin!
any late night opinions? how yall this morning, just got a cab back from da bars cause if not im in TROUBLE!!
who be up in this piece?????
cause at least I can dump some at .0011 and buy more when it dips again!
what are the supposed MM signals again?
looks like a strong .001 close, lets see some UTs tomorrow
heard, but wife wouldnt let me go last night:(
where are all the tfn signs in toronto today?????
I got my friends XLs and mine 2xl, im only 180 6'3 and XXL fits good!
Good thinking, your insights are killer!;)
I am off to work also, back at a summer job cause they need help since one girl just had a baby this other person is out for 2 weeks cause of an eye injury and the office manager is out in hawaii, can always use the money too. the place is a sportfishing landing in san diego, we do mostly tuna trips all summer, I am down to hook up a charter once this thing runs! the place is H&M Landing, i gotta work 2-11p tonight, and earlier the rest of the week, it is not the easiest office to watch the market but they havent fired me yet and ive been back a week, later, have a safe 4th, gonna be a big week:)
San Diego Ca
got here about 10:30am had to sign for it via usps
sweatshirt is 80% cotton 20% poly label says fight brand clothing, www.fightbrandclothing.com
the fight network on front
and
get it on on the back.
tshirts are 100% cotton same label, and to me seem better quality than the sweatshirts, but it is summer and I live in san diego, so dont need a super thick sweatshirt, should be great for nights out!;)
anyone other than analyze going to the WFA in LA on the 22nd?
hopefully can cash out some funds and do it right ya know!